Showing 1 to 3 of 3 results


Car T-cell Immunotherapy Extends Life of Gastric Cancer Patients by 40%
A world-first clinical trial in China shows that Car T-cell immunotherapy significantly increases the lifespan of patients with advanced gastric or gastro-oesophageal junction cancer by approximately 40%, offering a potential paradigm shift in the treatment of solid tumors, according to results publ...
Car T-cell Immunotherapy Extends Life of Gastric Cancer Patients by 40%
A world-first clinical trial in China shows that Car T-cell immunotherapy significantly increases the lifespan of patients with advanced gastric or gastro-oesophageal junction cancer by approximately 40%, offering a potential paradigm shift in the treatment of solid tumors, according to results publ...
Progress
48% Bias Score


CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
Progress
40% Bias Score

18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.

18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.
Progress
40% Bias Score
Showing 1 to 3 of 3 results